Next Article in Journal
Using Telemedicine to Provide Education for the Symptomatic Patient with Chronic Respiratory Disease
Next Article in Special Issue
Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest
Previous Article in Journal
Exploring the Clinical Utility of Gustatory Dysfunction (GD) as a Triage Symptom Prior to Reverse Transcription Polymerase Chain Reaction (RT-PCR) in the Diagnosis of COVID-19: A Meta-Analysis and Systematic Review
Previous Article in Special Issue
Hippo Signaling Pathway as a New Potential Target in Non-Melanoma Skin Cancers: A Narrative Review
 
 
Review

Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis

1
Department of Biochemistry and Pharmacology, “Victor Babe” University of Medicine and Pharmacy, Pta Eftimie Murgu Nr. 2, 300041 Timişoara, Romania
2
Center for Complex Networks Science, “Victor Babe” University of Medicine and Pharmacy, Pta Eftimie Murgu Nr. 2, 300041 Timişoara, Romania
3
Department of Dermatology and Venerology, “Victor Babe” University of Medicine and Pharmacy, Pta Eftimie Murgu Nr. 2, 300041 Timişoara, Romania
*
Author to whom correspondence should be addressed.
Academic Editor: Joanna Narbutt
Life 2021, 11(12), 1316; https://doi.org/10.3390/life11121316
Received: 19 October 2021 / Revised: 1 November 2021 / Accepted: 26 November 2021 / Published: 29 November 2021
(This article belongs to the Special Issue Frontiers of Dermatological Research)
Psoriasis is a chronic inflammatory, autoimmune-mediated disease that affects millions of individuals worldwide. Advances in treatment with biological agents represented by monoclonal antibodies, such as TNF-α inhibitors (TNFI), IL-17A and IL-12/23 antagonists have not only benefited from outstanding clinical efficacy with lower side effects compared to conventional systemic therapy, but also raised the standards towards therapeutic success, fact reflected in the greater Psoriasis Area and Severity Index (PASI) response rates. However, due to their relatively recent introduction in clinical practice, and despite their proven superior efficacy, further research is needed for monitoring the eventual changes in treatment-induced parameters, especially of metabolic origin. In this respect, initial reports stress on one particular comorbidity associated with psoriasis-obesity-which seems to be not only a risk and result of the disease, but also an adverse effect of long-term therapy with some biologics. The consequent drug-induced increase in body mass index (BMI) of patients suffering from psoriasis undergoing biological treatment appears to contribute to the progression of the disease, promote drug discontinuation and reduce overall clinical efficacy of monoclonal antibodies. Therefore, we review herein the impact of body weight (BMI) increase on the biological treatment of psoriasis, to further investigate on its relationship with the disease and aid on the management of treatment schemes that take into account individual characteristics of patients, such as body mass, for a more efficient and personalized therapy approach. View Full-Text
Keywords: psoriasis; body mass index; monoclonal antibodies; drug-induced weight gain psoriasis; body mass index; monoclonal antibodies; drug-induced weight gain
Show Figures

Figure 1

MDPI and ACS Style

Anghel, F.; Nitusca, D.; Cristodor, P. Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis. Life 2021, 11, 1316. https://doi.org/10.3390/life11121316

AMA Style

Anghel F, Nitusca D, Cristodor P. Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis. Life. 2021; 11(12):1316. https://doi.org/10.3390/life11121316

Chicago/Turabian Style

Anghel, Flavia, Diana Nitusca, and Patricia Cristodor. 2021. "Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis" Life 11, no. 12: 1316. https://doi.org/10.3390/life11121316

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop